Development and bioavailability improvement of imiquimod in the form of solid lipid nanoparticles

Abstract

Nanomaterials are the ideal carriers for biological applications because of their high bioavailability and biocompatibility. The primary focus of many researchers employing novel techniques has been fresh discoveries. Many methods have been used to create nanoparticles, which have potential applications in various illnesses. Solid Lipid Nanoparticle (SLN) drug delivery system has outstanding results in treating chronic diseases. Actinic keratoses (AK), known as sun keratoses or senile keratoses, are benign intraepithelial neoplasms caused by abnormal keratinocyte proliferation. Hence, in the present research, Imiquimod SLNs were fabricated using various concentrations of lipids, surfactants, and cryoprotectants. Cold high-pressure homogenization was shown to produce smaller particles with improved entrapment effectiveness. The Particle size ranges from (209.6±4.57 to 502.1±8.9 nm). Formulation IMB 3 which contain 1% w/w Glycerol Monostearate and 3% w/w Glyceryl Behenate as Lipid for SLNs preparation shows better results for Mean particle size (245.1±8.45), Zeta Potential (-41±1.2), PDI (0.39±0.03), % EE (64±0.79) and Loading Capacity (48±2.6) with % cumulative drug release of 89.74±3.5 after 24 hours.